O. J. L. Loosveld

University Medical Center Utrecht — Netherlands

Medicine · Health Sciences

21h-index3.0kcitations64works7.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(25), Gastric Cancer Management and Outcomes(16), Pancreatic and Hepatic Oncology Research(9), Cancer Treatment and Pharmacology(9), Hepatocellular Carcinoma Treatment and Prognosis(7)

Publications63 total

Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial
Journal of Clinical Oncology·2026
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial
The Lancet Oncology·2025· 18 cited
Blood Sample Collection in Randomized Controlled Trials for Biomarker Discovery and Validation: Experience of the PREOPANC-2 Trial
Annals of Surgical Oncology·2025· 2 citedOpen Access
First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases
JAMA Oncology·2024· 21 citedOpen Access
Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group
Annals of Oncology·2024· 12 citedOpen Access
Extrahepatic perfusion and incomplete hepatic perfusion after hepatic arterial infusion pump implantation: incidence and clinical implications
HPB·2024· 3 citedOpen Access
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial
HPB·2024· 2 citedOpen Access
Real life data and outcome of FOLFIRINOX use in metastatic pancreatic cancer patients in general hospitals in the Netherlands
Research Square (Research Square)·2023Open Access
LBA83 Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial
Annals of Oncology·2023· 54 citedOpen Access
LBA27 First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): Overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group
Annals of Oncology·2023· 10 citedOpen Access
Health-Related Quality of Life in Patients With Metastatic Colorectal Cancer Undergoing Systemic Therapy With or Without Maximal Tumor Debulking
Journal of the National Comprehensive Cancer Network·2023· 9 citedOpen Access
Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial
BMC Cancer·2023· 49 citedOpen Access
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group
The Lancet Oncology·2023· 153 citedOpen Access
Upfront palliative resection of primary tumor versus no resection in patients with synchronous metastatic colorectal cancer: The randomized phase 3 CAIRO4 study of the Dutch Colorectal Cancer Group (DCCG).
Journal of Clinical Oncology·2023· 5 cited
The effect of definitive chemoradiotherapy on quality of life in patients with esophageal cancer: Analysis of the Dutch population-based POCOP registry.
Journal of Clinical Oncology·2023
LBA21 FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group
Annals of Oncology·2022· 4 citedOpen Access
FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and/or <i>RAS</i>/<i>BRAFV600E-</i>mutated primary tumor: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group.
Journal of Clinical Oncology·2022· 13 cited
Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials
Gastric Cancer·2022· 18 citedOpen Access
Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment
JAMA Surgery·2021· 51 citedOpen Access
Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223
Prostate Cancer and Prostatic Diseases·2021· 12 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Cornelis J.A. Punt(14), Miriam Koopman(12), Mike S.L. Liem(10), Linda Mol(9), Ignace H. J. T. de Hingh(9), Mathijs P. Hendriks(9), Brigitte C.M. Haberkorn(9), Frans Erdkamp(8), Bas Groot Koerkamp(8), Jan Willem B. de Groot(8), Paul Hamberg(8), Maartje Los(7), Gijs A. Patijn(7), Johannes H.W. de Wilt(7), Bronno van der Holt(7), Aart van Bochove(6), Marco B. Polée(6), Jacob L. van Dam(6), Marjolein Y.V. Homs(6), Geertjan van Tienhoven(6)